L3VLUP
ProSign in

MMM · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MMMVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MMM
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMMMVRTX
Q3 202022 holders, $4.1bn31 holders, $21.9bn
Q4 202020 holders, $4.3bn30 holders, $18.4bn
Q1 202116 holders, $4.6bn31 holders, $15.4bn
Q2 202115 holders, $5.1bn30 holders, $12.7bn
Q3 202117 holders, $4.0bn35 holders, $10.1bn
Q4 202117 holders, $3.6bn28 holders, $12.4bn
Q1 202218 holders, $2.2bn23 holders, $16.1bn
Q2 202221 holders, $2.0bn25 holders, $18.1bn
Q3 202226 holders, $2.2bn22 holders, $18.4bn
Q4 202222 holders, $2.1bn28 holders, $18.4bn
Q1 202321 holders, $1.8bn26 holders, $21.4bn
Q2 202321 holders, $1.8bn27 holders, $24.7bn
Q3 202323 holders, $1.8bn33 holders, $24.3bn
Q4 202327 holders, $2.5bn32 holders, $28.6bn
Q1 202429 holders, $3.3bn31 holders, $29.8bn
Q2 202430 holders, $4.8bn29 holders, $33.4bn
Q3 202434 holders, $5.9bn27 holders, $33.5bn
Q4 202433 holders, $5.8bn26 holders, $28.5bn
Q1 202526 holders, $7.2bn21 holders, $35.4bn
Q2 202521 holders, $6.9bn21 holders, $32.3bn
Q3 202524 holders, $6.8bn22 holders, $25.9bn
Q4 202520 holders, $6.6bn26 holders, $31.8bn
Q1 202626 holders, $7.0bn25 holders, $31.8bn
Q2 202631 holders, $7.1bn26 holders, $34.6bn
MMM

3M Co

Holders
31
Reported value
$7.1bn
Buyers
19
Sellers
22

Breadth -3 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MMM (14)

ARK Investment Management LLC, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Freestone Grove Partners LP, Moore Capital Management LP, Point72 Asset Management LP, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Voloridge Investment Management LLC, Walleye Capital LLC, Winton Group Ltd

Only VRTX (9)

Arrowstreet Capital LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, MFS Investment Management, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →